Best Investments for 2015
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.
The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.
Roche's $1 billion-plus investment in Foundation Medicine aims to expand use of genetic testing to develop new, more effective drugs.
A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.
TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off Monday in San Francisco.
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics
while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a
reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV